Current Illinois CancerCare Clinical Trials

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma

Study Number: MK-6482-011

Study Summary:
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

Status: Open

Open in Peoria only

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Alyssa, 309-243-3626, awagner@illinoiscancercare.com

Study Link

« Search Again